{"entity":{"type":"insider","cik":"0001853327","url":"/insider/0001853327","json_url":"/insider/0001853327.json","name":"Burrows Scott L","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":25,"n_filings":14,"first":"2021-12-28","last":"2026-08-05","span_basis":"filed_date"},"name_variants":[{"name":"Burrows Scott L","source":"filing","n_filings":14,"first_seen":"2021-12-28","last_seen":"2026-08-05"}],"transactions":[{"id":5814877,"accession":"0001636282-26-000100","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001636282-26-000100","line_url":"/filing/0001636282-26-000100","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":95.56946666666667,"price_display":"95.57","price_state":"stated","total_value":716771.0,"total_display":"716,771.00","total_whole":"716,771","shares_owned_after":100394.0,"shares_owned_after_display":"100,394","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-08-03","filed_date":"2026-08-05","scope":"insider","n_lines":3},{"id":5746459,"accession":"0001636282-26-000088","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001636282-26-000088","line_url":"/filing/0001636282-26-000088","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":87.7386,"price_display":"87.74","price_state":"stated","total_value":658039.5,"total_display":"658,039.50","total_whole":"658,040","shares_owned_after":99719.0,"shares_owned_after_display":"99,719","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-02","scope":"insider","n_lines":2},{"id":5876969,"accession":"0001853327-26-000008","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001853327-26-000008","line_url":"/filing/0001853327-26-000008","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":87.13333333333334,"price_display":"87.13","price_state":"stated","total_value":1307000.0,"total_display":"1,307,000.00","total_whole":"1,307,000","shares_owned_after":97994.0,"shares_owned_after_display":"97,994","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-25","filed_date":"2026-06-26","scope":"insider","n_lines":2},{"id":5987034,"accession":"0001636282-26-000076","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001636282-26-000076","line_url":"/filing/0001636282-26-000076","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":71.058264,"price_display":"71.06","price_state":"stated","total_value":532936.98,"total_display":"532,936.98","total_whole":"532,937","shares_owned_after":97994.0,"shares_owned_after_display":"97,994","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-06-01","filed_date":"2026-06-03","scope":"insider","n_lines":3},{"id":5924516,"accession":"0001853327-26-000005","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001853327-26-000005","line_url":"/filing/0001853327-26-000005#line-2","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12500.0,"shares_display":"12,500","price_per_share":71.37,"price_display":"71.37","price_state":"stated","total_value":892125.0,"total_display":"892,125.00","total_whole":"892,125","shares_owned_after":97994.0,"shares_owned_after_display":"97,994","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-05-01","filed_date":"2026-05-01","scope":"insider"},{"id":5759424,"accession":"0001853327-26-000003","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001853327-26-000003","line_url":"/filing/0001853327-26-000003","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7500.0,"shares_display":"7,500","price_per_share":49.343466666666664,"price_display":"49.34","price_state":"stated","total_value":370076.0,"total_display":"370,076.00","total_whole":"370,076","shares_owned_after":99294.0,"shares_owned_after_display":"99,294","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-04-01","filed_date":"2026-04-03","scope":"insider","n_lines":2},{"id":6157455,"accession":"0001636282-26-000028","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001636282-26-000028","line_url":"/filing/0001636282-26-000028","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2500.0,"shares_display":"2,500","price_per_share":40.648,"price_display":"40.65","price_state":"stated","total_value":101620.0,"total_display":"101,620.00","total_whole":"101,620","shares_owned_after":98194.0,"shares_owned_after_display":"98,194","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-03-03","filed_date":"2026-03-03","scope":"insider","n_lines":2},{"id":4436876,"accession":"0001636282-25-000095","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-25-000095","line_url":"/filing/0001636282-25-000095#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18428.0,"shares_display":"18,428","price_per_share":16.26,"price_display":"16.26","price_state":"stated","total_value":299639.28,"total_display":"299,639.28","total_whole":"299,639","shares_owned_after":97994.0,"shares_owned_after_display":"97,994","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-02","filed_date":"2025-09-03","scope":"insider"},{"id":2522856,"accession":"0001636282-24-000062","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001636282-24-000062","line_url":"/filing/0001636282-24-000062#line-1","is_derivative":false,"issuer_cik":"0001636282","issuer_name":"Spyre Therapeutics, Inc.","issuer_ticker":"SYRE","issuer_name_source":null,"issuer_url":"/issuer/0001636282","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18531.0,"shares_display":"18,531","price_per_share":28.173,"price_display":"28.17","price_state":"stated","total_value":522073.863,"total_display":"522,073.86","total_whole":"522,074","shares_owned_after":116422.0,"shares_owned_after_display":"116,422","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-03","filed_date":"2024-09-05","scope":"insider"},{"id":7880149,"accession":"0001567619-23-004671","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-23-004671","line_url":"/filing/0001567619-23-004671#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":291.0,"shares_display":"291","price_per_share":15.2634,"price_display":"15.26","price_state":"stated","total_value":4441.6494,"total_display":"4,441.65","total_whole":"4,442","shares_owned_after":59115.0,"shares_owned_after_display":"59,115","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-06","filed_date":"2023-03-08","scope":"insider"},{"id":8305431,"accession":"0001567619-23-004270","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-23-004270","line_url":"/filing/0001567619-23-004270","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1434.0,"shares_display":"1,434","price_per_share":15.827107949790795,"price_display":"15.83","price_state":"stated","total_value":22696.0728,"total_display":"22,696.07","total_whole":"22,696","shares_owned_after":38424.0,"shares_owned_after_display":"38,424","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-02","filed_date":"2023-03-02","scope":"insider","n_lines":2},{"id":8305426,"accession":"0001567619-23-004270","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-23-004270","line_url":"/filing/0001567619-23-004270#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":416.0,"shares_display":"416","price_per_share":16.1663,"price_display":"16.17","price_state":"stated","total_value":6725.1808,"total_display":"6,725.18","total_whole":"6,725","shares_owned_after":39840.0,"shares_owned_after_display":"39,840","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-28","filed_date":"2023-03-02","scope":"insider"},{"id":6355537,"accession":"0001567619-22-006494","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001567619-22-006494","line_url":"/filing/0001567619-22-006494#line-3","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10.0,"shares_display":"10","price_per_share":16.4449,"price_display":"16.44","price_state":"stated","total_value":164.449,"total_display":"164.45","total_whole":"164","shares_owned_after":35256.0,"shares_owned_after_display":"35,256","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-07","filed_date":"2022-03-07","scope":"insider"},{"id":6355533,"accession":"0001567619-22-006494","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001567619-22-006494","line_url":"/filing/0001567619-22-006494#line-2","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":293.0,"shares_display":"293","price_per_share":16.8591,"price_display":"16.86","price_state":"stated","total_value":4939.7163,"total_display":"4,939.72","total_whole":"4,940","shares_owned_after":35266.0,"shares_owned_after_display":"35,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-04","filed_date":"2022-03-07","scope":"insider"},{"id":6332269,"accession":"0001567619-22-006228","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-006228","line_url":"/filing/0001567619-22-006228#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":420.0,"shares_display":"420","price_per_share":17.7527,"price_display":"17.75","price_state":"stated","total_value":7456.134,"total_display":"7,456.13","total_whole":"7,456","shares_owned_after":22259.0,"shares_owned_after_display":"22,259","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-03","scope":"insider"},{"id":4869476,"accession":"0000899243-21-049940","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-049940","line_url":"/filing/0000899243-21-049940#line-1","is_derivative":false,"issuer_cik":"0001787306","issuer_name":"Arcutis Biotherapeutics, Inc.","issuer_ticker":"ARQT","issuer_name_source":null,"issuer_url":"/issuer/0001787306","owner_cik":"0001853327","owner_name":"Burrows Scott L","owner_display_name":"Burrows Scott L","owner_url":"/insider/0001853327","role":"Officer (Chief Financial Officer)","role_mark":"O","role_mark_label":"Officer (Chief Financial Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Financial Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12560.0,"shares_display":"12,560","price_per_share":20.0748,"price_display":"20.07","price_state":"stated","total_value":252139.488,"total_display":"252,139.49","total_whole":"252,139","shares_owned_after":22679.0,"shares_owned_after_display":"22,679","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-12-27","filed_date":"2021-12-28","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":25,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":25,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":25},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001636282","name":"Spyre Therapeutics, Inc.","url":"/issuer/0001636282","role":"Officer (Chief Financial Officer)","n_filings":9,"first_seen":"2024-09-05","last_seen":"2026-08-05"},{"type":"issuer","type_label":"ISSUER","cik":"0001787306","name":"Arcutis Biotherapeutics, Inc.","url":"/issuer/0001787306","role":"Officer (Chief Financial Officer)","n_filings":5,"first_seen":"2021-12-28","last_seen":"2023-03-08"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001853327","retrieved_at":"2026-08-23T16:18:05+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}